Article

Rates of antiretroviral resistance among HIV-infected patients with and without a history of injection drug use.

British Columbia Centre for Excellence in HIV/AIDS, St. Paul's Hospital, Vancouver, Canada.
AIDS (Impact Factor: 6.56). 08/2005; 19(11):1189-95. DOI: 10.1097/01.aids.0000176219.48484.f1
Source: PubMed

ABSTRACT There exist concerns regarding the potential for elevated rates of antiretroviral resistance among HIV-infected injection drug users (IDUs) prescribed highly active antiretroviral therapy (HAART), however, no population-based study has examined if IDUs have elevated rates of antiretroviral resistance in comparison to non-IDUs.
To evaluate the time to the development of antiretroviral resistance among antiretroviral-naive patients with and without a history of injection drug use.
In British Columbia there is a province-wide HIV/AIDS treatment program that provides antiretrovirals free of charge. We examined all antiretroviral-naive patients initiating HAART between 1 August 1996 and 30 September 2000 and who were followed to 31 March 2002. The main outcome measure was the time to class-specific antiretroviral resistance. Cumulative antiretroviral resistance rates among IDUs and non-IDUs were evaluated using Kaplan-Meier methods and relative hazards were estimated using Cox regression.
Overall, 1191 antiretroviral-naive patients initiated HAART during the study period. Resistance mutations were observed in 298 (25%) subjects during the first 30 months of HAART. In comparison with non-IDUs, the risk of protease inhibitor resistance [relative hazard (RH), 0.9; 95% confidence interval (CI), 0.5-1.6] and non-nucleoside reverse transcriptase inhibitor resistance (RH, 1.5; 95% CI, 1.0-2.2) were similar among IDUs, and there were no differences in the rates of resistance to the sub-classes of nucleoside reverse transcriptase inhibitors.
Resistance to all major classes of antiretrovirals were similar among IDUs and non-IDUs after 30 months of follow-up. These findings should help to allay fears that prescribing HAART to IDUs may result in elevated rates of resistance.

1 Bookmark
 · 
81 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: For patients with both HIV/HCV coinfection and substance addiction, multidisciplinary teams can facilitate coordination of care and improve clinical outcomes. Such teams should include HIV/HCV treatment providers, mental health specialists, case managers, social workers, and substance abuse counselors.
    Federal practitioner for the health care professionals of the VA, DoD, and PHS 02/2014; 31(Suppl. 1):37S-40S.
  • [Show abstract] [Hide abstract]
    ABSTRACT: HIV-positive people who use drugs (PWUDs) are particularly vulnerable for suboptimal access to highly active antiretroviral therapy (HAART). We conducted a systematic review to identify factors associated with suboptimal HAART access among this population. Studies evaluating HAART access among active PWUDs as a primary outcome, presenting multivariate analysis and conducted after January 1997 were included. Of 122 studies matching the search criteria, only 14 (11.4 %) met the inclusion criteria. All selected studies were prospective cohorts and included young adults, 13 were conducted in North America or western Europe and one in Ukraine. Selected studies measured HAART access using different strategies, however, all identified PWUDs as less likely to receive HAART, when compared to those who never used drugs or former PWUDs. Additional factors associated with suboptimal HAART access include: recent incarceration, lack of health insurance, unstable housing, depression, non-white ethnicity, female PWUDs, and health professionals stigma/prejudice. Factors associated with higher rates of HIV-treatment access included: alcohol and/or drug addiction treatment (especially methadone maintenance therapy), regular source of primary care, treatment and care from the same provider (most of the time) and larger physician experience in HIV-management. PWUDs face a synergy of social and structural factors that influence their suboptimal access to HAART, struggling with poor living conditions, inadequate access to specialized care and stigma/discrimination from health professionals. Renewed strategies and effective interventions should be developed and scaled-up, in order to assure equitable HAART access, decrease morbidity and mortality among PWUDs.
    Current HIV/AIDS Reports 12/2013;
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Evolutionary biologists are often interested in finding correlations among biological traits (or attributes) across a number of species, as such correlations may lead to testable hypotheses about the underlying function. Because some species are more closely related than others, computing and visualizing these correlations must be done in the context of the evolutionary tree that relates the species. Although dozens of visualizations for correlated traits have been developed over the decades, the recent explosive growth in the number of traits and species has created a need for a visualization that can scale to dozens of traits mapped to thousands of species and their evolutionary tree to allow the interactive exploration of complex interactions. In this paper, we introduce Det., called detective, an evolutionary tree visualization that allows biologists to see multiple attributes of leaf nodes. We describe a new tree layout algorithm to represent different branch lengths and several visualization and intereaction techniques to address user requirements. We also report informal feedbacks we collected from evolutionary biologists.